Key result
Elevated cardiac troponin levels in acute decompensated heart failure correlate with increased short- and long-term mortality and readmission rates, serving as an independent prognostic biomarker.
Why the study?
Does elevated cardiac troponin predict mortality and readmission in patients with acute heart failure?
Does elevated cardiac troponin predict mortality and readmission in patients with acute heart failure?
Cardiac troponin is an important independent biomarker for predicting short- and long-term mortality and readmissions in patients with acute heart failure.
May aid risk stratification in acute HF; leaves open whether troponin integration alters management or outcomes.
Cardiac troponin (cTn) is the primary biomarker for the diagnosis of myocardial necrosis in an acute coronary syndrome (ACS). cTn levels can also be elevated in many other conditions, including heart failure, with significant prognostic value. An elevated cTn level can be found in both acute and chronic heart failure and its presence is believed to be due to multiple different pathophysiological processes. In acute decompensated heart failure (AHF), an elevated cTn level has been repeatedly shown to correlate with increased short- and long-term mortality and, to a lesser extent, readmission rates. These associations have been demonstrated with both I and T isoforms of cTn, as well as when troponin is measured with conventional assays or new high-sense assays. In multimarker models, cTn has repeatedly been found to be an independent predictive variable enhancing prognostic ability of the model. cTn is therefore an important biomarker for prognosis in AHF.
No takes yet. Share an insight, caveat, or question.
Wettersten et al. (2015) conducted a review in Acute Heart Failure. Elevated cardiac troponin (cTn) levels was evaluated on Short- and long-term mortality and readmission rates. Elevated cardiac troponin levels in acute decompensated heart failure correlate with increased short- and long-term mortality and readmission rates, serving as an independent prognostic biomarker.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: